Online citations, reference lists, and bibliographies.
← Back to Search

Development Of Ipilimumab: Contribution To A New Paradigm For Cancer Immunotherapy.

A. Hoos, R. Ibrahim, A. Korman, K. Abdallah, D. Berman, V. Shahabi, K. Chin, R. Canetta, R. Humphrey
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal antibody ipilimumab to block CTLA-4 and potentiate antitumor T-cell responses. Animal studies first provided insight into the ability of an anti-CTLA-4 antibody to cause tumor regression, particularly in combination regimens. Early clinical studies defined ipilimumab pharmacokinetics and possibilities for combinability. Phase II trials of ipilimumab in advanced melanoma showed objective responses, but a greater number of patients had disease stabilization. In a phase III trial, ipilimumab was the first agent to demonstrate an improvement in overall survival in patients with previously treated, advanced melanoma. The adverse event profile associated with ipilimumab was primarily immune-related. Adverse events can be severe and life-threatening, but most were reversible using treatment guidelines. Ipilimumab monotherapy exhibits conventional and new patterns of activity in advanced melanoma, with a delayed separation of Kaplan-Meier survival curves. The observation of some new response patterns with ipilimumab, which are not captured by standard response criteria, led to novel criteria for the evaluation of immunotherapy in solid tumors. Overall, lessons from the development of ipilimumab contributed to a new clinical paradigm for cancer immunotherapy evolved by the Cancer Immunotherapy Consortium.
This paper references
10.1073/PNAS.95.17.10067
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
10.4049/jimmunol.171.11.6251
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
T. Keler (2003)
10.1097/PPO.0b013e3181eb336d
Regulatory T Cells: Overcoming Suppression of T-Cell Immunity
T. Golovina (2010)
10.1200/jco.2009.27.15_suppl.3020
Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
D. Berman (2009)
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
10.1158/0008-5472.CAN-08-3529
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
L. Fong (2009)
10.1084/JEM.194.4.481
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
A. van Elsas (2001)
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma
Jedd D. Wolchok (2010)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1097/CMR.0b013e328333bbc8
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
S. Agarwala (2010)
10.1200/jco.2009.27.15_suppl.9008
Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
O. Hamid (2009)
10.1056/NEJMOA020177
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
L. Zhang (2003)
10.1158/1078-0432.CCR-10-0569
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1093/jnci/djq310
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
10.1200/JCO.2008.21.6432
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
A. Fournier (2009)
Immunological aspects of local radiotherapy: clinical relevance.
S. Formenti (2010)
10.1073/pnas.0830997100
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
10.1038/ncponc1183
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
F. S. Hodi (2008)
10.1038/nm0303-269
Immunotherapy: past, present and future
T. Waldmann (2003)
10.1097/CMR.0b013e3283364a37
Complete regression of a previously untreated melanoma brain metastasis with ipilimumab
N. Schartz (2010)
10.1073/PNAS.94.15.8099
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
E. Kwon (1997)
10.1007/s10637-009-9376-8
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
E. Hersh (2009)
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
M. Morse (2005)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1016/j.cellsig.2009.09.013
Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.
Turgut Cetindere (2010)
10.1634/THEONCOLOGIST.12-7-864
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
10.1200/jco.2009.27.15_suppl.5138
Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC).
S. Slovin (2009)
10.1084/jem.20082492
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
K. Peggs (2009)
10.1002/cncr.24951
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
10.1159/000386035
The concept of immunological surveillance.
F. Burnet (1970)
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Darryl A. Oble (2009)
10.1038/sj.bjc.6602934
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
K. Hiraoka (2006)
10.1016/S0084-3873(08)70468-1
Costimulation Blockade With Belatacept in Renal Transplantation
F. Tedla (2006)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1634/theoncologist.2008-0166
Cancer and immune response: old and new evidence for future challenges.
L. de la Cruz-Merino (2008)
10.1084/JEM.177.1.165
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
P. Tan (1993)
10.1200/JCO.2008.26.15_SUPPL.3022
Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
D. Berman (2008)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Cellular and humoral aspects of the hypersensitive states : a symposium held at the New York academy of medicine
H. Lawrence (1959)
10.1200/JCO.2008.17.8954
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
10.1038/nrc2051
Immunostimulatory monoclonal antibodies for cancer therapy
I. Melero (2007)
10.1146/ANNUREV.IMMUNOL.22.012703.104803
The three Es of cancer immunoediting.
Gavin P Dunn (2004)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1126/SCIENCE.1496399
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
P. Linsley (1992)
10.1111/j.1600-065X.2008.00649.x
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
K. Peggs (2008)
10.1200/JCO.2008.21.1771
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
C. Willett (2009)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1097/01.cji.0000208259.73167.58
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
A. Maker (2006)
10.1073/pnas.0806075105
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
C. Liakou (2008)
10.1245/ASO.2005.03.536
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
Concurrent infiltration by CD 8  T cells and CD 4  T cells is a favorable prognostic factor in non - small - cell lung carcinoma
K Hiraoka (2006)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
10.1073/PNAS.96.26.15074
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.
E. Kwon (1999)
10.1097/01.CJI.0000211341.88835.AE
A clinical development paradigm for cancer vaccines and related biologics.
A. Hoos (2007)
10.1016/S1074-7613(00)80123-5
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
P. Shrikant (1999)
10.11501/3169195
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Y. Yang (1997)
10.1016/1074-7613(94)90071-X
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
10.1200/JCO.2010.28.15_SUPPL.8523
Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.
D. Lawrence (2010)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1200/JCO.2007.12.7837
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
10.1007/s00262-008-0653-8
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
M. B. Mokyr (1998)
10.1038/jid.2008.101
Immunotherapy for advanced melanoma.
L. Fang (2008)
10.1093/annonc/mdq013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
10.1146/annurev.immunol.021908.132544
Immune therapy for cancer.
M. Dougan (2009)
10.1200/JCO.2010.28.15_SUPPL.7531
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
T. Lynch (2010)
10.1016/J.VACCINE.2007.06.067
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
L. Finke (2007)
10.1200/jco.2009.27.15_suppl.9034
Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.
J. Lutzky (2009)
10.1200/jco.2009.27.15_suppl.9037
Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity.
A. Amin (2009)
10.1016/j.cell.2009.08.006
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo (2009)
10.1136/bmj.1.5023.841
Cancer—A Biological Approach*
M. Burnet (1957)
10.1136/bmj.1.5022.779
Cancer—A Biological Approach
M. Burnet (1957)
10.1016/S1470-2045(09)70334-1
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A. Hurwitz (2000)
10.1200/JCO.2007.14.6423
Next generation of immunotherapy for melanoma.
J. Kirkwood (2008)
10.1007/S11912-009-0053-Z
Betting on immunotherapy for melanoma
M. Sznol (2009)
10.1093/INTIMM/8.4.519
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
M. Krummel (1996)
10.1084/JEM.190.3.355
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)



This paper is referenced by
10.2147/CMAR.S52543
Real-world impact of education: treating patients with ipilimumab in a community practice setting
B. Ledezma (2013)
10.2217/imt-2019-0199
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
A. Ambavane (2020)
10.1155/2013/423829
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
B. Chmielowski (2013)
Preclinical Development Regression of Human Prostate Cancer Xenografts inMice by AMG 212 / BAY 2010112 , a Novel PSMA / CD 3-Bispeci fi c BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
M. Friedrich (2012)
Predicting analysis times in randomized clinical trials with cancer immunotherapy
Bristol-Myers Squibb (2016)
10.5772/59860
Toxicities of New Drugs for Melanoma Treatment and their Management
P. Savoia (2015)
10.1007/s00262-011-1012-8
Camouflage and sabotage: tumor escape from the immune system
I. Poschke (2011)
10.7812/TPP/14-042
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
D. Bota (2015)
10.1177/1078155212459100
Ipilimumab for advanced melanoma: A pharmacologic perspective
V. Trinh (2013)
10.1097/JTO.0b013e31822e28fc
Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome
F. Shepherd (2011)
10.1007/978-3-319-05104-8_6
Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress
Axel Hoos (2014)
Ipilimumab for advanced melanoma: A pharmacologic perspective
Pharm Practice (2012)
Predictive Biomarkers and Personalized Medicine Speci fi c Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-In fi ltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi (2012)
10.1093/annonc/mds213
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M. Reck (2013)
10.1158/1078-0432.CCR-12-2982
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
P. Ascierto (2013)
10.2217/fon-2018-0607
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
N. Carreau (2019)
10.1001/jamaoncol.2018.6258
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
M. Disis (2019)
10.2147/CPAA.S45884
Use of ipilimumab in the treatment of melanoma
U. Acharya (2013)
10.5348/IJCRI-201651-CR-10639
A case of Stevens–Johnson syndrome in a patient on ipilimumab
M. Pathria (2016)
10.1002/cam4.371
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
L. Camacho (2015)
10.1007/978-3-030-31113-1_2
Evolution of Response Criteria in Immunotherapy
Y. Liu (2020)
10.1111/pcmr.12847
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
P. LoRusso (2019)
The Analysis of Problem and Creation of Classification of Renal Side Effects During Immunotherapy
Liliia Zrielykh (2019)
10.1111/j.1365-2133.2011.10507.x
Roles of the immune system in skin cancer
S. Rangwala (2011)
10.1136/postgradmedj-2012-131533
Novel cancer therapies: treatments driven by tumour biology
Ramya Ramaswami (2013)
10.1055/s-0034-1375961
DILI and drug development: a regulatory perspective.
M. Avigan (2014)
10.1007/s11864-012-0201-9
Integrating New Therapies in the Treatment of Advanced Melanoma
B. Curti (2012)
10.1186/s40425-017-0276-8
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
H. Kaufman (2017)
10.1158/1078-0432.CCR-12-2214
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
I. Melero (2013)
Uso de ipilimumab en pacientes con melanoma metastásico. Experiencia en el Hospital Médica Sur
Jose Manuel Ruiz-Morales (2014)
10.2217/imt.12.143
Adoptive T-cell transfer in melanoma.
O. Itzhaki (2013)
10.1093/annonc/mds647
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
C. Zielinski (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar